Cargando…

Mitochondrial dysfunction and alcohol-associated liver disease: a novel pathway and therapeutic target

Detalles Bibliográficos
Autores principales:	Abdallah, Mohamed A., Singal, Ashwani K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054548/ https://www.ncbi.nlm.nih.gov/pubmed/32296016 http://dx.doi.org/10.1038/s41392-020-0128-8

Ejemplares similares

Therapeutic targets in alcohol-associated liver disease: progress and challenges
por: Adekunle, Ayooluwatomiwa Deborah, et al.
Publicado: (2023)

Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches
por: Merino‐Vico, Ana, et al.
Publicado: (2022)

Covid-19 and alcohol associated liver disease
por: Deutsch-Link, Sasha, et al.
Publicado: (2022)

In search for novel strategies towards neuroprotection and neuroregeneration: is PPARα a promising therapeutic target?
por: Moreno, Sandra, et al.
Publicado: (2015)

Integrated Multidisciplinary Management of Alcohol-associated Liver Disease
por: Holbeck, Malia, et al.
Publicado: (2023)

NLRP3 inflammasome as a novel therapeutic target for Alzheimer’s disease
por: Zhang, Yun, et al.
Publicado: (2020)

Editorial: Alcohol-associated liver disease—From pathogenesis to treatment
por: Kharbanda, Kusum K., et al.
Publicado: (2022)

Hydrogen sulfide controls peripheral nerve degeneration and regeneration: a novel therapeutic strategy for peripheral demyelinating disorders or nerve degenerative diseases
por: Jung, Junyang, et al.
Publicado: (2014)

The quest for lower alcoholic wines
por: Caballero, Antonio, et al.
Publicado: (2017)

Diabetes Mellitus Predicts Occurrence of Cirrhosis and Hepatocellular Cancer in Alcoholic Liver and Non-alcoholic Fatty Liver Diseases
por: Raff, Evan J., et al.
Publicado: (2015)

The cGAS-STING pathway: a therapeutic target in chromosomally unstable cancers
por: Yan, Haiyan, et al.
Publicado: (2023)

Janus kinase signaling as risk factor and therapeutic target for severe SARS‐CoV‐2 infection
por: Solimani, Farzan, et al.
Publicado: (2021)

Regulatory T cells as a therapeutic approach for inflammatory bowel disease
por: Laukova, Marcela, et al.
Publicado: (2023)

Highlight: The Mystery of Mitochondrial Genomes
por: Venton, Danielle
Publicado: (2013)

Targeting programmed death ligand 2/repulsive guidance molecule b pathway: a novel strategy to subdue tumor immunotherapy resistance to anti‐programmed death 1/programmed death ligand 1
por: Xiang, Yuancai, et al.
Publicado: (2023)

Identification of a Novel Molecular Target for Alcohol Dependence
por: Carney, Rosalind S.E.
Publicado: (2018)

Wine secondary aroma: understanding yeast production of higher alcohols
por: Gonzalez, Ramon, et al.
Publicado: (2017)

EphB2: potential therapeutic target for Alzheimer’s disease
Publicado: (2011)

Gasdermin: a novel therapeutic target for tumour treatment by activating anti-tumour immunity
por: Fu, Caiyun
Publicado: (2020)

Highlight: Mitochondrial First Steps Found in Jakobid Protists
por: Venton, Danielle
Publicado: (2013)

At Long Last: The Me(3)Si Group as a Masked Alcohol
por: Roy, Avijit, et al.
Publicado: (2021)

Somatic mutant clone screening: scan for novel NASH target genes in mouse liver
por: Lan, Tian, et al.
Publicado: (2023)

Microglial lactate metabolism as a potential therapeutic target for Alzheimer’s disease
por: Zhao, Yingjun, et al.
Publicado: (2022)

Lymphatic metastasis in non‐small cell lung cancer: recent discoveries and novel therapeutic targets
por: Diao, Xiayao, et al.
Publicado: (2022)

Identifying therapeutic targets for schizophrenia
por: Montague-Cardoso, Karli
Publicado: (2021)

Global burden of cirrhosis and liver cancer due to alcohol: the past, present, and the future
por: Xie, Chencheng, et al.
Publicado: (2023)

Liver-brain axis with alcohol: Role of fibroblast growth factor 21 (FGF21)
por: Zhang, Ke, et al.
Publicado: (2023)

Fumarate hydratase inhibition activates innate immunity via mitochondrial nucleic acid release
por: Li, Xiang, et al.
Publicado: (2023)

Targeted next-generation sequencing expands the spectrum of mitochondrial disorders
por: Hahn, Si Houn
Publicado: (2012)

Potential mechanisms by which impaired ketogenesis links metabolism to T‐cell dysfunction in patients with severe COVID‐19
por: Wang, Bin, et al.
Publicado: (2022)

Niemann-Pick disease and platelet dysfunction
Publicado: (2012)

Greek gods and the double-edged sword of liver regeneration
por: Kattner, Aila Akosua
Publicado: (2021)

Innate immune signaling and immunothrombosis: New insights and therapeutic opportunities
por: Ryan, Tristram A. J., et al.
Publicado: (2022)

ASGR1: an emerging therapeutic target in hypercholesterolemia
por: Zhao, Wenqi, et al.
Publicado: (2023)

Engineered nucleus-free mesenchymal stem cells (MSCs) for the targeted delivery of therapeutics to disease site
por: Schwartz, Zander, et al.
Publicado: (2022)

Advances in Liver Transplantation: where are we in the pursuit of transplantation tolerance?
por: Safinia, Niloufar, et al.
Publicado: (2021)

Prostaglandin regulation of type 2 inflammation: From basic biology to therapeutic interventions
por: Oyesola, Oyebola O., et al.
Publicado: (2021)

Functional interaction between sensory neurons and mast cells in the early stage of house dust mite-induced type 2 inflammation and itch: a novel therapeutic target of allergic disease
por: Tsang, Miranda Sin-Man, et al.
Publicado: (2020)

Alcohol‐Associated Liver Disease Before and After COVID‐19—An Overview and Call for Ongoing Investigation
por: Moon, Andrew M., et al.
Publicado: (2021)

Mitochondrial Complex I deficiency: guilty in Parkinson’s disease
por: Vos, Melissa
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r5fs883f16atgbuljh6c9o2t0l